Sands Capital acquired 3.86 Million Ultragenyx Pharmaceutical shares worth $162 Million. That's 0.47% of their equity portfolio (39th largest holding). The investor owns 4.56% of the outstanding Ultragenyx Pharmaceutical stock. The first Ultragenyx Pharmaceutical trade was made in Q2 2023. Since then Sands Capital bought shares one more times and sold shares on two occasions. The investor's estimated purchase price is $168 Million, resulting in a loss of 4.0%.
Benzinga Pro data, Ultragenyx Pharmaceutical (NASDAQ: RARE ) reported Q1 sales of $100.50 million. Earnings fell to a loss of $163.97 million, resulting in a...
Benzinga, about 1 year agoRelated Stocks: RARE , ASND , CERE , ACCD , SRRA , MGNX , BAX , WRBY , IMRX , ABOS , AADI , ICVX , BGNE , ARDX , BIIB , BSX , PPD , ADPT ,
GuruFocus, over 2 years agoCinctive Capital Management LP increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 92.0% during the 2nd quarter, according to...
Transcript Daily, over 2 years ago